RxDoctor Payments Data

Brandon Burelle

Psychiatric/Mental Health · Denver, CONPI 1881241131

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,814 and has fallen 92.5% since, to $212 in 2025. Among psychiatric/mental health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,251in general payments, 2019–2025

Across 141 payments — averaging $37.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$481
  • Alkermes, Inc.$439
  • Neurocrine Biosciences, Inc.$323
  • Axsome Therapeutics, Inc.$309
  • Avadel CNS Pharmaceuticals, LLC$267
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,22199%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,251 in reported general payments places this provider in the 95th percentile of 873 psychiatric/mental health providers in Colorado.

See all psychiatric/mental health providers in Colorado

Most prescribed under Part D

DrugClaimsCost to plans & patients
LamictalLamotrigine13$5,914
DayvigoLemborexant11$3,766
Methylphenidate Hcl14$1,038
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$951
Liothyronine Sodium14$523
Duloxetine Hcl14$438
Clonazepam13$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Dayvigo$12$3,76611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 873 psychiatric/mental health providers in Colorado.

Other psychiatric/mental health in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →